Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Iovance Biotherapeutics Inc is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Iovance Biotherapeutics employs 319 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $11.47 |
|---|---|
| 52-week range | $6.18 - $27.96 |
| 50-day moving average | $12.10 |
| 200-day moving average | $17.38 |
| Wall St. target price | $30.77 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.30 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.47 from 2022-07-01
| 1 week (2022-06-28) | 4.46% |
|---|---|
| 1 month (2022-06-03) | 46.11% |
| 3 months (2022-04-01) | N/A |
| 6 months (2022-01-05) | -31.81% |
| 1 year (2021-07-02) | -56.65% |
|---|---|
| 2 years (2020-07-02) | -60.57% |
| 3 years (2019-07-05) | 24.53 |
| 5 years (2017-07-05) | 57.12% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -30.9% |
| Return on equity TTM | -59.76% |
| Profit margin | 0% |
| Book value | $3.51 |
| Market capitalisation | $1.8 billion |
TTM: trailing 12 months
We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.
Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.
Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $6.18 up to $27.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.9061. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).
Iovance Biotherapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M. D.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.